Identification of novel germline polymorphisms governing capecitabine sensitivity.
O'Donnell PH, Stark AL, Gamazon ER et al.
Publication Details
Comprehensive information about this research publication
Abstract
Summary of the research findings
Capecitabine, an oral 5-fluorouracil (5-FU) prodrug, is widely used in the treatment of breast, colorectal, and gastric cancers. To guide the selection of patients with potentially the greatest benefit of experiencing antitumor efficacy, or, alternatively, of developing toxicities, identifying genomic predictors of capecitabine sensitivity could permit its more informed use.
Up to 84 East Asian ancestry lymphoblastoid cell lines, up to 164 European ancestry lymphoblastoid cell lines, up to 173 African ancestry lymphoblastoid cell lines, up to 82 African American lymphoblastoid cell lines
Study Statistics
Key metrics and study information
AI-Generated Summary
AI-generated by DNAGENICSIndependent AI summary of health and genetic findings from the published study
Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.
AI Summary In Progress
Our AI-generated summary of this publication is being prepared. Please check back soon.